NTUS Natus Medical Incorporated

Bryant M. Moore, Ph.D. and Eric J. Guerin Appointed to Natus Board of Directors

Bryant M. Moore, Ph.D. and Eric J. Guerin Appointed to Natus Board of Directors

PLEASANTON, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced the appointments of Bryant M. Moore, Ph.D. and Eric J. Guerin to the Company's Board of Directors. With these appointments, the Natus Board will be expanded to eight members.

“We are pleased to welcome Bryant and Eric to the Natus Board and look forward to benefitting from their medical device experience and business counsel as we move beyond ‘One Natus’ to a more focused growth-oriented strategy,” said Joshua H. Levine, Chairperson of the Board of Directors.

Dr. Moore has served as the Director of Strategic partnerships at the University of North Carolina's Office of Technology Commercialization since 2015. Prior to his current role, Dr. Moore served as the Global Head of Refractive R&D at Abbott Laboratories and he served in multiple leadership roles in research and development at Medtronic. Dr. Moore brings decades of significant leadership experience in technology assessment, research, new product development, and platform technology management that will support Natus’ efforts in innovation and portfolio management.

“I am excited to join the Natus Board and help the Company achieve long term growth through a robust innovation pipeline complemented by external acquisition,” said Dr. Moore.

Mr. Guerin serves as Chief Financial Officer of CDK Global, Inc., the largest provider of automotive dealership solutions including retailing, CRM, financing, parts and service, IT infrastructure and dealership operations. Prior to this current role, Mr. Guerin served in financial leadership and business development roles at Corning Incorporated, Flowserve Corporation, Alcon and Johnson & Johnson. Mr. Guerin brings significant financial and business experience with large, complex medical device organizations as well as experience in innovative service and subscription business models to the Board.

“Natus’ neurodiagnostic portfolio is a market leader, and I am looking forward to joining the Board to help the Company build on its core platforms to offer comprehensive solutions to healthcare customers,” said Mr. Guerin.

“Bryant and Eric are joining Natus at an exciting time and will be invaluable resources to the Company as we strengthen internal product development and other growth-oriented business processes,” said Jonathan Kennedy, President and Chief Executive Officer.

About Natus Medical Incorporated

Natus is a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages. Additional information about Natus Medical can be found at

Natus Medical Incorporated

B. Drew Davies

Executive Vice President and Chief Financial Officer

(925) 223-6700



EN
18/08/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Natus Medical Incorporated

 PRESS RELEASE

ArchiMed completes acquisition of Natus Medical Incorporated for $1.2 ...

ArchiMed completes acquisition of Natus Medical Incorporated for $1.2 billion total equity value MIDDLETON, Wis., July 21, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today that the MED Platform II fund of ArchiMed (“ArchiMed”), a leading investment firm focused exclusively on the healthcare industry, completed the acquisition of Natus. In accordance with the definitive ...

 PRESS RELEASE

Natus Medical Announces First Quarter 2022 Financial Results

Natus Medical Announces First Quarter 2022 Financial Results  Q1-2022 Key ResultsRevenue (millions)$119.8 • Total revenue increased 4.2% compared to Q1 2021• Generated $8.9 million in operating cash flowGAAP EPS$0.06 Non-GAAP EPS$0.22     MIDDLETON, Wis., May 05, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, today announced financial results for the three months ended March 31, 2022...

 PRESS RELEASE

Natus Medical Incorporated to be acquired by ArchiMed Group for $33.50...

Natus Medical Incorporated to be acquired by ArchiMed Group for $33.50 per share in cash Highlights: •        Transaction values Natus Medical, Incorporated at approximately $1.2 billion total equity value•        Pre-announces preliminary financial results for the first quarter ended March 31, 2022 MIDDLETON, Wis., April 18, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announce...

 PRESS RELEASE

Natus Medical to Hold 2022 First Quarter Financial Results Conference ...

Natus Medical to Hold 2022 First Quarter Financial Results Conference Call on May 6th PLEASANTON, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2022 first quarter financial results after the close of the market on Thursday, May 5th. Natus management will host a conference call on Friday, May 6th at 8:00 a.m. Eastern...

 PRESS RELEASE

Natus Medical Announces Fourth Quarter 2021 Financial Results

Natus Medical Announces Fourth Quarter 2021 Financial Results  Q4-2021 Key ResultsRevenue (millions)$128.7 • Revenue increased 8% compared to Q4 2020• Revenue increased 14% compared to full year 2020• $12.8 million in operating cash flow for Q4 2021• $63.9 million in operating cash flow for the year 2021GAAP EPS$0.05 Non-GAAP EPS$0.47     PLEASANTON, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathw...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch